Titan Pharmaceuticals Reports 8-K with Key Corporate Changes
| Field | Detail |
|---|---|
| Company | Titan Pharmaceuticals Inc |
| Form Type | 8-K |
| Filed Date | Oct 1, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, corporate-governance, financials
TL;DR
Titan Pharma dropped an 8-K: acquisitions, control changes, exec shifts, and financials are all in play.
AI Summary
Titan Pharmaceuticals, Inc. filed an 8-K on October 1, 2025, reporting on several material events. These include the completion of an acquisition or disposition of assets, material modifications to security holder rights, changes in control of the registrant, and updates regarding directors and officers, including compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate events at Titan Pharmaceuticals, which could impact its business operations, financial structure, and shareholder value.
Risk Assessment
Risk Level: medium — The filing details significant corporate events like acquisitions, changes in control, and modifications to security holder rights, which inherently carry medium risk due to potential impacts on the company's future direction and value.
Key Players & Entities
- Titan Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- October 1, 2025 (date) — Date of earliest event reported
FAQ
What specific assets were acquired or disposed of by Titan Pharmaceuticals?
The filing indicates the completion of an acquisition or disposition of assets but does not specify the details of these transactions.
What were the material modifications to the rights of security holders?
The 8-K reports material modifications to the rights of security holders, but the specific nature of these modifications is not detailed in the provided text.
Were there any changes in control of Titan Pharmaceuticals?
Yes, the filing explicitly lists 'Changes in Control of Registrant' as an item being reported, indicating a change in control has occurred.
What specific changes occurred regarding directors or officers?
The filing mentions 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers,' suggesting updates in leadership and compensation.
When was this 8-K report filed and what is the earliest event date?
The report was filed as of October 1, 2025, and the date of the earliest event reported is also October 1, 2025.
Filing Stats: 975 words · 4 min read · ~3 pages · Grade level 11 · Accepted 2025-10-01 16:20:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TTNP Nasdaq Capital Mark
Filing Documents
- titanpharma_8k.htm (8-K) — 42KB
- 0001829126-25-007823.txt ( ) — 205KB
- ttnp-20251001.xsd (EX-101.SCH) — 3KB
- ttnp-20251001_lab.xml (EX-101.LAB) — 33KB
- ttnp-20251001_pre.xml (EX-101.PRE) — 22KB
- titanpharma_8k_htm.xml (XML) — 4KB
03. Material Modification to Rights of Security Holders
Item 3.03. Material Modification to Rights of Security Holders. At the Effective Time, stockholders of TTNP immediately prior to the completion of the Merger ceased to have any rights as stockholders of TTNP other than the right to receive the Stockholder Consideration in accordance with the Merger Agreement. The information set forth in Item 2.01 of this Report is incorporated herein by reference.
01. Changes
Item 5.01. Changes in Control of Registrant. The information set forth in Item 2.01 of this Report is incorporated herein by reference.
02. Departure
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 1, 2025, effective upon the Effective Time, (i) TTNP's directors and officers offered their resignations for serving in such capacities, at the request of Black Titan and not because of any disagreement with TTNP regarding any matter related to TTNP's operations, policies or practices, and (ii) Chay Weei Jye was appointed as the sole director and acting secretary of TTNP.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 2.1 Merger and Contribution and Share Exchange Agreement, dated as of August 19, 2024, by and among Titan Pharmaceuticals, Inc., TTNP Merger Sub, Inc., KE Sdn. Bhd., and BSKE Ltd. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC on August 19, 2024). 104 Cover Page Interactive Data (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TITAN PHARMACEUTICALS, INC. By: /s/ Chay Weei Jye Chay Weei Jye Chief Executive Officer Date: October 1, 2025 2